![]() | |||
AGENDA | |||
12:30 – 1:30 | Registration | ||
1:30 – 1:40 | Welcome Bob Buderi, Editor in Chief, Xconomy | ||
1:40 – 1:50 | Opening Remarks Douglas Williams, EVP, Research and Development, Biogen Idec | ||
1:50 – 2:15 | Profile 1: RNAi Therapeutics, Alnylam, and The Carrot Seed John Maraganore, CEO, Alnylam Pharmaceuticals | ||
2:15 – 2:45 | Panel: New Models for Collaboration Richard Brudnick, VP, Business Development, Biogen Idec Robert Urban, Head, J&J Innovation Center, Boston Jason Rhodes, President and CFO, Epizyme Rob Armstrong, former VP, Global External Research and Development, Eli Lilly (moderator) | ||
2:45 – 3:15 | Chat: Thoughts on the Past, Present, and Future of Biotech Michael Bonney, CEO, Cubist Pharmaceuticals Bob Buderi, Editor in Chief, Xconomy (moderator) | ||
3:15 – 3:45 | Networking Break | ||
3:45 – 4:10 | Profile 2: Gene Surgery With CRISPR/Cas9: The Editas Medicine Story Kevin Bitterman, Interim CEO, Editas Medicine; Partner, Polaris Partners Feng Zhang, Professor of Biomedical Engineering, MIT | ||
4:10 – 4:35 | Profile 3: Gene Regulation and Contrarian Drug Development: The Syros Pharmaceuticals Story Nancy Simonian, CEO, Syros Pharmaceuticals | ||
4:35 – 5:05 | Panel: New Alternatives for Financing Roger Stein, Chief Analytics Officer, State Street Global Exchange Katrine Bosley, Entrepreneur-in-residence, The Broad Institute (moderator) | ||
5:05 – 5:30 | Profile 4: A Bottoms-Up View of the Microbiome: The Seres Health Story David Berry, CEO, Seres Health; Partner, Flagship Ventures | ||
5:30 – 6:30 | Networking Reception | ||
REGISTER NOW: xconomyforum68.eventbrite.com | |||